menu
    • menu
    [{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Limertinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aosaikang Pharmaceutical \/ Innovent Biologics","highestDevelopmentStatusID":"10","companyTruncated":"Aosaikang Pharmaceutical \/ Innovent Biologics"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Limertinib","moa":"EGFR TK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aosaikang Pharmaceutical \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Aosaikang Pharmaceutical \/ Innovent Biologics"}]

    Find Clinical Drug Pipeline Developments & Deals for Limertinib

    Menu

    Limertinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aosaikang Pharmaceutical

                            China arrow
                            BioTrinity 2025
                            Not Confirmed

                            Aosaikang Pharmaceutical

                            China arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Limertinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Innovent Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Innovent and ASK Pharm Announce NMPA Approval of Limertinib for Lung Cancer

                            Details : ASK120067 (limertinib) is an oral third-generation EGFR TKI with proprietary rights, approved by NMPA for the treatment of adults with locally advanced or metastatic EGFR T790M-mutated NSCLC.

                            Product Name : ASK120067

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 16, 2025

                            Lead Product(s) : Limertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Innovent Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aosaikang Pharmaceutical

                            China arrow
                            BioTrinity 2025
                            Not Confirmed

                            Aosaikang Pharmaceutical

                            China arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Limertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Innovent Biologics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Innovent And Ask Pharm Collaborate on Limertinib For Lung Cancer Treatment

                            Details :

                            Product Name : ASK120067

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 10, 2024

                            Lead Product(s) : Limertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Innovent Biologics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth